BactoByte

Company Overview

Snapshot

Founded in June 2017 by Miron Krokhmal, Valery Brodsky, and Vladimir Glukhman, BactoByte operates with 1–10 employees. The company has secured one disclosed funding round from one investor, Rationalwave Capital Partners, to advance its bacterial diagnostics technology.

Business overview

BactoByte is a Health Tech & Life Sciences company focused on developing a bacterial diagnostics system. The company's core technology aims to provide rapid bacterial diagnostics and antibiotic screening capabilities, enabling caregivers to improve patient outcomes, reduce misdiagnoses, and lower healthcare costs. BactoByte operates in the Digital Healthcare sector, specifically within Digital Medical Diagnostics, and serves the healthcare industry, targeting providers in geomarkets including Asia, Europe, and North America.

Company Intelligence Q&A

When was BactoByte founded?

BactoByte was founded in June 2017 by Miron Krokhmal, Valery Brodsky, and Vladimir Glukhman.

What is BactoByte's primary mission?

BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capabilities to improve outcomes, reduce misdiagnoses, and lower healthcare costs.

What is BactoByte's current product stage?

BactoByte's product, a bacterial diagnostics system, is currently in the R&D stage, focusing on rapid diagnostics and antibiotic screening.

What markets does BactoByte target?

BactoByte targets geomarkets including Asia, Europe, and North America with its bacterial diagnostics system.